Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Maria Kinigopoulou"'
Autor:
Katerina Arvaniti, Anastasia Papadioti, Maria Kinigopoulou, Vassiliki Theodorou, Konstantinos Skobridis, Georgios Tsiotis
Publikováno v:
Proteomes, Vol 2, Iss 3, Pp 363-381 (2014)
Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has n
Externí odkaz:
https://doaj.org/article/d25cd1a7f3f94383bc4e6658b157315e
Autor:
V. Polychronidou, Dimitrios Alivertis, M. Filippidou, A. Giannousi, C. Georgis, Alexios Brentas, Vassiliki Theodorou, Nikoleta Ntemou, Maria Kinigopoulou, Konstantinos Skobridis, Marina Gogou, Pinelopi Voulgari, P. Fouka
Publikováno v:
RSC Advances. 6:61458-61467
We revisited the classical synthetic procedure for imatinib synthesis providing an improved and optimized approach in the preparation of a series of new imatinib analogues. The proposed methodology effectively overcomes certain problematic steps, sav
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8f3236c02510d86163989adf9ee01eb
https://doi.org/10.1039/c6ra09812f
https://doi.org/10.1039/c6ra09812f
Autor:
Georgios Tsiotis, Katerina Arvaniti, Konstantinos Skobridis, Maria Kinigopoulou, Anastasia Papadioti, Vassiliki Theodorou
Publikováno v:
Proteomes
Volume 2
Issue 3
Pages 363-381
Proteomes, Vol 2, Iss 3, Pp 363-381 (2014)
Volume 2
Issue 3
Pages 363-381
Proteomes, Vol 2, Iss 3, Pp 363-381 (2014)
Imatinib mesylate is the leading compound to treat chronic myeloid leukemia (CML) and other cancers, through its inhibition of Bcr-Abl tyrosine kinases. However, resistance to imatinib develops frequently, particularly in late-stage disease and has n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e18e66b196b37286cc1d84734e6ba59
Novel imatinib derivatives with altered specificity between Bcr-Abl and FMS, KIT, and PDGF receptors
Autor:
Nicola Brownlow, N J Dibb, Alison Russell, Maria Kinigopoulou, Andreas G. Tzakos, Konstantinos Skobridis, Jan Domin, Serafim Kiriakidis, Roberta Sala, Emilia Giannousi, Vassiliki Theodorou, Rakhee Chauhan
Publikováno v:
ChemMedChem. 5(1)
Imatinib is a clinically important ATP analogue inhibitor that targets the tyrosine kinase domain of the intracellular Abl kinase and the PDGF receptor family. Imatinib has revolutionised the treatment of chronic myeloid leukaemia, which is caused by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b67d278516b254238fefeab87fc3fc7
http://ora.ox.ac.uk/objects/uuid:a6fa9129-6312-4967-beb4-bd53709cec25
http://ora.ox.ac.uk/objects/uuid:a6fa9129-6312-4967-beb4-bd53709cec25
Autor:
Maria Kinigopoulou, Konstantinos Skobridis, Aris Karkatsoulis, Vassiliki Theodorou, Valentine Ragoussis
A new synthetic route to primary amides via N-tritylamides was developed. The initially formed N-tritylamides, derived from acylation of tritylamine by activated carboxylic acid derivatives, were deprotected with trifluoroacetic acid at room temperat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c03a4f3ce978bbfac10ac007a9f1c0
http://olympias.lib.uoi.gr/jspui/handle/123456789/9794
http://olympias.lib.uoi.gr/jspui/handle/123456789/9794
